Leukemia ture. By assaying at physiological temperatures, however, we were able to demonstrate that, apart from lower GR levels, T-ALL and AML samples (leukemia subgroups relatively resistant to GC-induced cell kill) had receptors with reduced affinity.
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Follicular lymphoma in advanced stages continues to be a therapeutic challenge with respect to curability. Encouraging results regarding clinical and molecular remission of follicular lymphoma are seen in patients who received combination therapy (R-CHOP) consisting of CHOP (cyclophosphamid, doxorubicin, vincristin, prednisone) and rituximab, the monoclonal CD20 antibody. A less effective therapy may jeopardize a patient's chance for remission, of which, molecular remission seems to be a prerequisite for long disease-free intervals. There are few reports [2] [3] [4] about reactivation of HBV during the treatment of hematological malignancies with rituximab in addition to concomitant or previous chemo-or immunsuppressive therapy (CHOP, fludarabine, prednisone). Confounding factors were present in each case (Table 1 ) leaving an unclear relationship between HBV reactivation and the monoclonal CD20 antibody. In order to elucidate this situation we report our experiences in an HBV-carrying patient who developed severe hepatitis after R-CHOP.
A 47-year-old man with cervical lymphadenopathy and more than 10% weight loss within the past 6 months was diagnosed with follicular lymphoma, grade 1. Staging procedures showed 60% infiltration of bone marrow (BM), enlarged (2-4 cm) lymph nodes on both sides of the diaphragm, among them at the porta hepatis and splenomegaly (16 × 17 × 6 cm). The molecular status was determined by BCL2/IgH-PCR (sensitivity 1:10 000) and CDR3-PCR (sensitivity 1:100) in peripheral blood (PB) and BM. Translocation (14;18) and clonal IgH rearrangement were detected in PB and BM (Table 2) , vincristine 2 mg, days 1-5: prednisolone 100 mg/day, day 22: next cycle). Therapy was well tolerated. On day 116, the sixth cycle was cancelled due to rapid increase of liver enzymes. Within 2 weeks the patient developed a severe icteric hepatitis with bilirubin 39.80 mg/dl, PT 24%, ALAT 2850 U/l. Reactivation of HBV was confirmed by high levels of HBV in the serum corresponding to nt 1896 precore mutant genomes only. From day 131 to day 190 he received lamivudine 100 mg daily p.o. Clinical course, serological data and molecular monitoring are shown in Figure 1 and Table 2 . Within 3 weeks the patient recovered from hepatitis with normalization of serologic parameters. On days 144 and 204 (50 and 110 days after last rituximab infusion), no CD20 + B lymphocytes were detectable in PB. HBV serology did not change, he is still HBsAg positive, anti-HBs negative, HBe-Ag negative, anti-HBe positive. HBV-DNA level returned to Ͻ5 pg/ml and remained below the detection limit. With regard to follicular lymphoma the patient is presently in clinical and molecular remission.
When our patient developed severe icteric hepatitis due to HBV reactivation a possibly contributory role of rituximab had to be taken into account (Table 1) . Further investigations revealed the link to pre- core mutant HBV. Within the past few years, the presence of HBV with a nucleotide mutation of the precore region, notably at position 1896, has been established as a risk factor for hepatitis flare-up with a fulminant course in chemotherapy-treated patients. 5 During hepatitis the elevated HBV levels in our patient could be attributed to genomes of the nt 1896 precore mutant only. The quoted reports (Table 1) on Leukemia HBV reactivation during or after therapy including rituximab do not contain characteristics of the reactivated virus. HBV serology, eg HBeAg negativity/anti-HBe positivity could give a clue to the presence of a precore mutant HBV, whereby HBs-Ag negativity does not exclude its presence. 5, 6 Our case illustrates the importance of identifying risk factors for HBV reactivation including viral factors prior to therapy. Precore mutant HBV is prone to reactivation and patients carrying this virus are at risk for fulminant hepatits. In these cases prophylactic treatment with lamivudine is strongly recommended. 5, 7 The clinical course of hepatitis in our patient confirms the efficacy of lamivudine in controlling HBV replication.
8 HBV was not reactivated and hepatitis did not return when lamivudine was discontinued. Direct cell killing by CD8 + cytotoxic T lymphocytes is thought to be the cause of liver injury (hepatitis) but is also a part of the host's immune attack against HBV. In the case of withdrawal of cytotoxic or immunosuppressive drugs (cycled chemotherapy) restoration of immune response results in rapid destruction of infected hepatocytes. This T cell activity also provides help for B cell response to HBV. Decrease of HBV load in our patient persisted under full activity of rituximab indicated by the absence of peripheral blood CD20 + B cells. HBV serology did not change. Rituximab depletes CD20 + B cells but not plasma cells, thereby leaving serum immunoglobulin levels almost unchanged. While it is possible that CD20 antibody therapy inhibits novel antibody formation, its role for former virus infections or reactivations of dormant viruses remains a speculative one.
We conclude that HBV serology should be part of the routine screening before initiating R-CHOP therapy. Determination of HBV-DNA levels is recommended during therapy. If a precore mutant is present, prophylactic therapy with lamivudine seems justified. 
TO THE EDITOR
De novo and acquired drug resistance limit the effectiveness of nucleoside analogue chemotherapy, and the responsible molecular mechanisms are under intense study. Lack of intracellular drug accumulation is an important and commonly identified mechanism of anticancer nucleoside resistance (for review see Galmarini et al
. Intracellular nucleoside drug accumulation is determined by (1) cellular plasma membrane nucleoside transport capacity, and (2) the balance of catabolic and anabolic cytosolic enzyme activities. The major route of cellular entry is via the nucleoside transporters (NTs). Five NTs have been cloned in humans, including two equilibrative transporters (hENT1, hENT2) and three concentrative transporters (hCNT1, hCNT2, hCNT3). However, hENT1 appears to be the major determinant of nucleoside drug uptake. Once inside the cell, the key enzyme in the conversion of a nucleoside analogue to its cytotoxic nucleotide form is deoxycytidine kinase (dCK). In opposition to dCK are the 5′-nucleotidases, which cleave phosphate groups from the 5′-carbon group of nucleoside monophosphates. Although high 5′-nucleotidase activity is associated with drug resistance, the responsible 5′-nucleotidases are not completely defined. One leading candidate is CN-II; two other 5′-nucleotidases which have yet to be evaluated in this role are dNT-I and ectonucleotidase.
We report the case of a patient with mantle cell lymphoma/ leukemia who, as is typical for this disease, exhibited resistance to nucleoside chemotherapy. We demonstrated impaired nucleoside analogue accumulation and fludarabine resistance in this patient's circulating lymphoma cells, and performed molecular analyses to explore potential mechanisms of nucleoside analogue resistance in mantle cell neoplasia.
A 61-year-old Caucasian man presented in 1996 with disseminated mantle cell lymphoma (MCL), confirmed by histologic and immunophenotypic analysis. He was treated with multiple chemotherapy regimens, including fludarabine, to which his malignancy was clinically resistant. As his malignancy progressed, he developed a mantle cell leukemia. The patient succumbed to his malignancy in May 2000. The patient's peripheral blood was sampled during a floridly leukemic phase, 1 week prior to his death, when his circulating malignant cell count was 115 000 cells/ml. Comparative peripheral blood samples were obtained from three healthy volunteers and 21 patients with nucleoside-naive chronic lymphocytic leukemia (CLL). Mononuclear cells (PBMC) were separated by Ficoll-Paque centrifugation (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and washing.
Because the patient did not respond favorably to fludarabine treatment, the isolated MCL cells were tested for their response to fludarabine exposure. Chemosensitivity was assessed by Promega 
